Oncotarget is a weekly peer reviewed publishing platform that puts out medical reports regarding oncology. The paper’s first paper came out in 2010 and is currently under the administration of the editors in chief Andrei V. Gudkov and Mikhail Blagosklonny. The two are research experts at Roswell Park Center Institute and have an undeterred commitment to provide the scientific community with accurate information on several topics, one of it being the development of cancer treatment.In 2017, the paper published a paper shedding light on how vitamin C helps combat cancerous cells. The article went ahead to compare the effects of using vitamin C with pharmaceutical drugs like 2-DG. Dr. Micheal P. Lisanti is the author of the material and stated that vitamin C is an affordable, organic and non-threatening treatment.
Micheal works as a professor at University of Salford with a specialty in translational medicine. He revealed that his team had has had a longstanding research in finding natural cancer treatments, among them being milk thistle, honey and CAPE.The study’s focus was on the operation of cancer cells and how vitamin C exceeds 2-DG in potency. The properties found proved that the right amounts would cease occurrence of tumors, metises, and progression of existing cancer. The most notable discovery was that it inhibits CSC formation, hence is a promising solution to cancer patients.Oncotarget has gained an unprecedented number of followers lately who are actively aware of the information available.
Their constructive criticism, insights, multi-authored commentaries fire up the scientific community and prompt scientists to advance their projects. Oncotarget has a high publishing standard that is maintenance by an expert team in addition to Mikhail and Andrei. The team played a key role in the acquisition of the 2013 Breakthrough Prize. Oncotarget has a license from Creative Commons Attribution and is the recipient of a 5.0 rating from Impact Factor in their 2015 review.Some of the studies under Oncotarget’s publishing rights include cardiology, pharmacology, metabolism, cardiology, cell and molecular biology, neuropathology, metabolism, and neuroscience. Oncotarget’s weekly review is a fast way of keeping people updated and allowing researchers to compare results expertly.
The start-up known as Mindstrong Health is one company that is focused on Neurological treatments. Mindstrong Health yesterday stated that they managed to get 14 million dollars in the initial round of financing. This was done with the intention of its neuropsychiatric treatment as well as its platform for diagnosis of such conditions. The company has come up with a platform which is Al-powered, and it is intended to observe interaction patterns via smartphones to monitor brain function. The platform looks to give biomarkers of cognition and biomarkers that are digital and uninterrupted. Dr. Tom Insel, who is the President and co-founder of Mindstrong Health said that he was impressed by the steps taken by the company to transform the scrolling or typing patterns of individuals while on their smartphones to a pinpoint way to measure the cognitive function. This new cutting edge approach to assess is just but a stepping stone for the foundation to invent better means of improving mental health. Check out LinkedIn to know more.
Foresite Capital led the initial round of financing alongside ARCH Venture, and they were later joined by One Mind Brain Health Impact Fund, Optum Ventures and also Berggruen Holdings, as the Calif-based company stated. Jim Tananbaum, the CEO of Foresite Capital, stated that the founding team of Mindstrong Health provides incomparable comprehension of the serious problems within the medical circles when it comes to attending to patients that have disorders related to cognitive health. The fusion of Rick, Tom and Paul’s knowledge technical vision and leadership, anyone intent on outcomes of such patients shall acquire a platform that is innovative which improves as well as greatly modernizes the provision of care to the patients.
Dr. Paul Dagum, CEO of Mindstrong Health, notes that modern medical care and treatment is dependent on measurement that is objective but despite this, mental health tracking depends on the reports coming from clinical environments. To get better results for mental disorder patients, the need to be measured objectively just like any other chronic disease.
Jim Tananbaum, who is the founding CEO at Foresite Capital Management. James has successfully led 21 healthcare companies these being the likes of Amerigroup, Jazz Pharmaceuticals, and Amira Pharmaceuticals. Before this, he founded and served as management at Theravance and also GelTex Pharmaceuticals, which got absorbed by Genzyme for 1.6 billion dollars later on.
James has a Master’s Degree attained in Harvard Med School and an additional MBA at Harvard Business School and later a BSSE and BS Yale University.
See more: https://inc42.com/buzz/forbes-midas-top-100-investors-2017/